Rivaroxaban in Stroke Prevention in Atrial Fibrillation (AF)

Atrial Fibrillation (AF)
Atrial fibrillation (AF) is the most common sustained cardiac rhythm disorder.

In AF, the upper chambers (atria) of the heart contract irregularly. As a result, the atria do not empty completely and blood does not flow properly, potentially allowing blood clots to form. These blood clots can break loose and travel to the brain, resulting in a stroke. The number of people with AF is forecast to increase approximately 2.5-fold by 2050 due to ageing of the population and improved survival following conditions that predispose to AF (such as a heart attack).

AF and Stroke
AF is an independent risk factor for stroke. Undiagnosed AF is a probable cause of many embolic strokes of undetermined source (formerly called ‘cryptogenic’ strokes), and stroke may be the first manifestation of AF.

About Stroke
Stroke is the second most common cause of death worldwide, responsible for 6.7 million deaths each year. Strokes can be classified into two major categories:

- Ischaemic Stroke
  Cause: Interruption of the blood supply due to a blockage (e.g. a blood clot)

- Haemorrhagic Stroke
  Cause: Rupture of a blood vessel which leads to bleeding inside the brain

Strokes may result in severely restricted movement, paralysis, loss of speech or vision which may be permanent, or even death. Stroke is also the leading cause of permanent disability among adults in the U.S.

Burden of AF-Related Stroke
AF-related stroke devastates lives and is a major healthcare burden.

The risk of stroke in patients with AF increases with age and with the addition of other risk factors (e.g. high blood pressure, previous stroke, and diabetes). Patients with AF who have multiple co-morbidities have a greater risk of stroke and represent the population most difficult to protect.

Furthermore, AF-related strokes are more severe, causing disability in more than half of patients and a worse outcome than strokes in patients without AF. Importantly, the burden of AF-related stroke is likely to become more marked in years to come as the number of people with AF increases.

Current Treatments and Clinical Challenges
Older therapy with Vitamin K antagonists (VKAs) such as warfarin makes effective anticoagulation harder than it needs to be for patients and physicians.

The limitations of VKAs can leave patients unprotected and for most AF patients, VKAs are no longer the recommended option for stroke prevention.

Novel oral anticoagulants (OACs) can overcome the limitations of older anticoagulants to prevent and/or treat venous and arterial thromboembolic (VAT) conditions.

Benefits of novel OACs include:
- Predictable anticoagulation without the need for routine coagulation monitoring or frequent dose adjustment
- Low risk of drug-drug interactions
- No significant food interactions

Rivaroxaban protects patients from blood clots across more VAT conditions than any other novel OAC.

Once-daily rivaroxaban provides highly effective stroke prevention without the need for routine coagulation monitoring. Importantly, rivaroxaban can prevent strokes without increasing the risk of heart attack and lowers the rate of the most feared intracranial and fatal bleeds, compared with warfarin. Furthermore, rivaroxaban is available in a specific dose evaluated for patients with renal impairment. Major gastrointestinal (GI) bleeds were more common with rivaroxaban than warfarin. As a once-daily dose, rivaroxaban halves the risk of discontinuation compared to warfarin. Once-daily dosing is preferred by patients with AF taking lifelong medications, and was shown to result in significantly higher adherence and persistence compared to twice-daily treatment.
Rivaroxaban Stroke Prevention in Atrial Fibrillation (AF) - Continued

Rivaroxaban Stroke Prevention in AF Regulatory Milestones

| 2011 | FDA APPROVED DECEMBER 2011 | For stroke prevention in AF |
| 2012 | EMA APPROVED DECEMBER 2012 | For stroke prevention in AF |
| 2013 | NICE RECOMMENDED MAR 2013 | |
| 2014 | ESC RECOMMENDED AUG 2014 | |

*UK’s NICE issued Final Guidance recommending rivaroxaban for adult National Health Service (NHS) patients in England and Wales with diagnosed non-valvular AF with one or more risk factors for stroke including patients who are not receiving warfarin due to the challenges and limitations it presents, as well as those who are not achieving stable INR control. The positive NICE appraisal was based on detailed analysis of the clinical and cost-effectiveness benefits of rivaroxaban.19

**European Society of Cardiology (ESC) issued updated Guidelines on the management of AF in August 2012 recommending rivaroxaban for the prevention of stroke in patients with AF26.***American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Rhythm Society (HRS) issued Guidelines for the management of AF in March 2014 recommending novel OACs, including rivaroxaban, for the management of AF and prevention of stroke29

About Rivaroxaban

Rivaroxaban is the most broadly indicated and most prescribed novel OAC28 and is marketed under the brand name Xarelto®. Rivaroxaban is approved for five indications across seven distinct areas of use, protecting patients across more venous and arterial thromboembolic (VAT) conditions than any other novel OAC:

- The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors
- The treatment of deep vein thrombosis (DVT) in adults
- The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip replacement surgery
- The prevention of VTE in adult patients undergoing elective knee replacement surgery
- The treatment of pulmonary embolism (PE) in adults
- The prevention of recurrent DVT and PE in adults
- The prevention of atherothrombotic events (cardiovascular death, heart attack or stroke) after an acute coronary syndrome in adult patients with elevated cardiac biomarkers when co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine

Whilst licences may differ from country to country, across all indications rivaroxaban is approved in more than 125 countries. Rivaroxaban was discovered by Bayer HealthCare, and is being jointly developed with Janssen Research & Development, LLC. Rivaroxaban is marketed outside the U.S. by Bayer HealthCare and in the U.S. by Janssen Pharmaceuticals, Inc. (a Johnson & Johnson Company).

Anticoagulant medicines are potent therapies used to prevent or treat serious illnesses and potentially life threatening conditions. Before initiating therapy with anticoagulant medicines, physicians should carefully assess the benefit and risk for the individual patient. Responsible use of rivaroxaban is a very high priority for Bayer, and the company has developed a Prescribers Guide for physicians and a ‘Xarelto’ Patient Card for patients to support best practice.

To learn more, please visit https://prescribe.xarelto.com

To learn more about thrombosis, please visit www.thrombosisadviser.com

To learn more about VAT, please visit www.VATspace.com

To learn more about ‘Xarelto’, please visit www.xarelto.com

References